Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (NCT06498635)
Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Who can join: Review the eligibility criteria below.
Location: NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (278 Sites)
Showing the first 25 of 278 sites.
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
- Kaiser Permanente-Oakland — Oakland, California
- Kaiser Permanente-Roseville — Roseville, California
- Kaiser Permanente Downtown Commons — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Kaiser Permanente-South Sacramento — Sacramento, California
- Kaiser Permanente-San Francisco — San Francisco, California
- Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
- Kaiser Permanente San Leandro — San Leandro, California
- Kaiser San Rafael-Gallinas — San Rafael, California
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara, California
- Kaiser Permanente-Santa Rosa — Santa Rosa, California
- Kaiser Permanente-South San Francisco — South San Francisco, California
- Torrance Memorial Physician Network - Cancer Care — Torrance, California
- Kaiser Permanente-Vallejo — Vallejo, California
- Kaiser Permanente-Walnut Creek — Walnut Creek, California
- Kaiser Permanente-Franklin — Denver, Colorado
📞 Contact the Study Coordinator
Phone: (870) 936-7066
Email: Emily.Carvell@bmhcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Non-Small Cell Carcinoma
- CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer — Los Angeles, California
- Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer — Jonesboro, Arkansas
- Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study — San Francisco, California
- Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study — Houston, Texas
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
Explore by condition: All Lung Non-Small Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.